Expression of IL4Rα and IL13Rα1 Are Associated With Poor Prognosis of Soft-tissue Sarcoma of the Extremities, Superficial Trunk, and Retroperitoneum

Kyoung Min Kim
Jeonbuk National University Medical School

Usama Khamis Hussein
Jeonbuk National University Medical School

See-Hyoung Park
Hongik University - Sejong Campus

Young Jae Moon
Jeonbuk National University Medical School

Zhongkai Zhang
Jeonbuk National University Medical School

Asmaa Gamal Ahmed
Jeonbuk National University Medical School

Ae-Ri Ahn
Jeonbuk National University Medical School

Ho Sung Park
Jeonbuk National University Medical School

Jung Ryul Kim
Jeonbuk National University Medical School

Kyu Yun Jang (kyjang@jbnu.ac.kr)
Chonbuk National University Medical School

Research

Keywords: soft tissue, sarcoma, IL4Rα, IL13Rα1, prognosis

DOI: https://doi.org/10.21203/rs.3.rs-114438/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

IL4Ra and IL13Ra1 are constituents of the type II IL4 receptor. Recently, IL4Ra and IL13Ra1 were reported to have roles in cancer progression and suggested as potential prognostic markers. However, studies on IL4Ra and IL13Ra1 in soft-tissue sarcomas have been limited.

Methods

This study investigated the expression of IL4Ra and IL13Ra1 in 89 soft-tissue sarcomas of the extremities, superficial trunk, and retroperitoneum.

Results

In human soft-tissue sarcomas, immunohistochemical expression of IL4Ra was significantly associated with IL13Ra1 expression. Nuclear and cytoplasmic expression of IL4Ra and IL13Ra1 were significantly associated with shorter survival of soft-tissue sarcoma patients in univariate analysis. Multivariate analysis indicated that nuclear expression of IL4Ra and IL13Ra1 were independent indicators of shorter overall survival (IL4Ra; \( p = 0.002 \), IL13Ra1; \( p = 0.016 \)) and relapse-free survival (IL4Ra; \( p = 0.022 \), IL13Ra1; \( p < 0.001 \)) of soft-tissue sarcoma patients. Moreover, the co-expression pattern of nuclear IL4Ra and IL13Ra1 was an independent indicator of shorter survival of soft-tissue sarcoma patients (overall survival; \( p < 0.001 \), relapse-free survival; overall \( p < 0.001 \)).

Conclusions

This study suggests IL4Ra and IL13Ra1 are associated with the progression of soft-tissue sarcoma, and the expression of IL4Ra and IL13Ra1 might be novel prognostic indicators of soft-tissue sarcoma patients.

Background

Cytokines and cytokine receptors have crucial roles in the regulation of the biologic mechanisms of immune cells and tumor cells [1, 2]. Recent advances in cancer biology reveal that cytokines and their receptors mediate cancer-related signaling. Especially, the IL4 receptor (IL4R) complex has been studied for its role in cancer progression [2, 3]. There are three types of receptor complexes that IL4 binds to [3, 4]. Type I IL4R is expressed on T-cells and NK cells and is composed of IL4Ra and IL2Ryc [1, 3, 4]. Type II IL4R is expressed on solid tumors and fibroblasts and is composed of IL4Ra and IL13Ra1 [2, 4, 5]. Type III IL4R is expressed on B-cells and monocytes and is composed of IL4Ra, IL13Ra1, and IL2Ryc [3]. Among these three types of IL4R complexes, type II IL4R is activated by binding of both IL4 and IL13, and studies on type II IL4R have focused on its expression on solid tumors [1–4, 6]. Higher expression of IL4Ra and IL13Ra1 was observed in various types of human cancers such as colorectal, breast, pancreatic, bladder, brain, and ovarian cancers [3, 7, 8]. In addition, elevated expression of IL4Ra and/or IL13Ra1 were associated with poor prognosis of glioblastoma [9], mesothelioma [10], breast cancer [11], renal cell carcinoma [12], and oral cavity squamous cell carcinoma patients [13]. These clinical impact of the IL4Ra and IL13Ra1 expression in human cancer has been associated with the role of IL4Ra/IL13Ra1 receptor complex in the proliferation and survival of cancer cells. The activation of IL4Ra/IL13Ra1 by IL4/IL13 stimulates JAK1/JAK2/JAK3-STAT6-mediated proliferation of cancer cells [1–3, 14]. Therefore, based on the relationship between the IL4/IL13, IL4R receptor complex, and JAK1/JAK2/JAK3-STAT6, there have been multiple clinical trials to treat human cancers via inhibition or blocking of the IL4Ra/IL13Ra1 pathway [1–3].

Soft-tissue sarcoma (STS) is a malignant tumor that originates from various types of mesenchymal tissue. Therefore, STS is not a single type of malignant tumor, but includes multiple types of soft tissue malignant tumors with diverse backgrounds [15]. However, despite the heterogeneity of this tumor type and the numerous histologic subtypes of STS, the incidence of STS is very low [16]. In addition, the study of the pathogenesis of STSs to achieve successful treatment of STSs is limited. Therefore, further study on the treatment of STS is needed. There have been recent advances in the understating of the role of cytokines and cytokine receptors in the development and progression of human cancers. Among the mesenchymal type of cancers such as rhabdomyosarcoma and osteosarcoma cells, it has been suggested that the IL4R pathway might be a therapeutic target of these types of cancers [16, 17]. Therefore, based on the structural relationship of IL4Ra and IL13Ra1 as the components of type II IL4R [1–3], we investigated the expression and clinicopathological significance of IL4Ra and IL13Ra1 in human STSs.
Methods

Soft-tissue sarcoma patients

In this study, STSs diagnosed between July 1998 and January 2013 at Jeonbuk National University Hospital were evaluated. STSs were reviewed according to the latest WHO classification of soft tissue tumors [15] and the 8th edition of the American Joint Committee Cancer Staging System [18]. Thereafter, specific subtypes of STS such as gastrointestinal stromal tumor, Kaposi sarcoma, and atypical lipomatous tumor were not included in this study. Because there is no stages for STSs of the head and neck, thoracic, and abdominal viscera in the latest staging system, the STSs of the extremities, superficial trunk, and retroperitoneum were included in this study [15, 18]. Finally, 89 cases of STSs with a complete medical history, histologic slides, and tissue blocks were included in this study. Information regarding clinicopathological variables of the STSs was obtained by review of the medical records. The clinicopathological factors considered in this study were the age of the patients, sex, tumor stage, tumor size, lymph node metastasis at diagnosis, distant metastasis at diagnosis, histologic grade, tumor differentiation, mitotic count, tumor necrosis, and histologic subtype of STS. This study was performed with approval by the institutional review board of Jeonbuk National University Hospital (IRB number, CUH 2015-09-024-002) and was performed in compliance with the Declaration of Helsinki. In this approval, written informed consent was waived because of the anonymous and retrospective nature of this study.

Immunohistochemical staining and scoring

The expression of IL4Rα and IL13Rα1 in STSs was evaluated by immunohistochemical staining of tissue microarray (TMA) sections. The TMA cores were obtained from the original paraffin-embedded tissue block after a review of original histologic slides. Two 3.0 mm cores per case were used to establish a TMA block from the area with the highest histologic grade without any degenerative change. The TMA tissue sections were deparaffinized and underwent an antigen retrieval procedure by boiling for 20 min with a microwave oven in a pH 6.0 antigen retrieval solution (DAKO, Glostrup, Denmark). The tissue sections were incubated with primary antibodies for IL4Rα (1:100, sc-165974, Santa Cruz Biotechnology, Santa Cruz, CA) and IL13Rα1 (1:100, sc-25849, Santa Cruz Biotechnology, Santa Cruz, CA) and visualized with the DAKO Envision system (DAKO, Carpinteria, CA). Immune-stained slides were scored according to staining intensity and stained area according to their expression in the cytoplasm or nuclei of tumor cells. The staining intensity was scored from zero to three (0; no staining, 1; weak staining, 2; intermediate staining, 3; strong staining) and the stained area was scored from zero to five (0; 0%, 1; 1%, 2; 2–10%, 3; 11–33%, 4; 34–66%, 5; 67–100%) [19–22]. The immunohistochemical staining score in each TMA core was obtained by adding a staining intensity score and the stained area score. Thereafter, because we used two TMA cores in each case, the sum of the immunohistochemical staining scores from two TMA cores was used as final immunohistochemical score. The final score ranged from zero to sixteen. The scoring was performed by two pathologists (KYJ and KMK) with consensus without clinical information under a multi-viewing microscope.

Statistical analysis

The positivity of immunohistochemical expression of IL4Rα and IL13Rα1 was determined by using receiver operating characteristic (ROC) curve analysis. An event in ROC curve analysis was defined as the death of a patient by STS, and the cut-off point was determined at the point with the highest area under the curve (AUC). The end-point of follow up was June 2014. The prognosis of STS patients was evaluated for overall survival (OS) and relapse-free survival (RFS). An event in OS analysis was the death of a patient from STS. The patients who were alive at the end-point of follow-up or died by other causes were censored. The duration of follow-up for OS analysis was determined from the date of operation to the date of the last contact. An event in RFS was a relapse of STS or death of the patients from STS. The patients who were alive without relapse at the end-point of follow-up or died by other causes were censored. The duration of follow-up for RFS analysis was determined from the date of operation to the date of the event or last contact. The prognostic values of potential prognostic factors were evaluated by performing univariate and multivariate Cox proportional hazards regression analysis and Kaplan-Meier survival analysis. The relationships between the potential prognostic clinicopathological factors were determined via Pearson's chi-square test. Statistical analysis was performed with SPSS software (IBM, version 22.0, Armonk, NY) and p values less than 0.05 being considered statistically significant.

Results

The association between the clinicopathologic variables and the expression of IL4Rα and IL13Rα1 in soft-tissue sarcomas
The immunohistochemical expression of IL4Ra and IL13Ra1 were seen in both the cytoplasm and the nuclei of tumor cells and representative images for the expression of IL4Ra and IL13Ra1 are presented in Fig. 1a. The cut-off points for the nuclear expression of IL4Ra (nIL4Ra), cytoplasmic expression of IL4Ra (cIL4Ra), nuclear expression of IL13Ra1 (nIL13Ra1), and cytoplasmic expression of IL13Ra1 (cIL13Ra1) were determined by ROC curve analysis (Fig. 1b). The cut-off points for nIL4Ra, cIL4Ra, nIL13Ra1, and cIL13Ra1 were nine, five, eleven, and ten, respectively (Fig. 1b). With these cut-off values, the positivity for nIL4Ra, cIL4Ra, nIL13Ra1, and cIL13Ra1 in various histologic subtypes of STS are presented in Table 1. Positivity for nIL4Ra was significantly associated with age ($p = 0.033$), higher tumor stage ($p < 0.001$), lymph node metastasis ($p = 0.034$), higher histologic grade ($p = 0.002$), increased mitotic count ($p < 0.001$), presence of tumor necrosis ($p = 0.020$), and expression of cIL4Ra ($p < 0.001$), nIL13Ra1 ($p < 0.001$), and cIL13Ra1 ($p = 0.003$) (Table 2). Positivity for cIL4Ra was significantly associated with higher tumor stage ($p = 0.012$), lymph node metastasis ($p = 0.027$), higher histologic grade ($p < 0.001$), increased mitotic count ($p = 0.003$), presence of tumor necrosis ($p = 0.022$), and expression of nIL13Ra1 ($p < 0.001$) and cIL13Ra1 ($p < 0.001$) (Table 2). The expression of nIL13Ra1 was significantly associated with higher tumor stage ($p < 0.001$), lymph node metastasis ($p = 0.015$), distant metastasis ($p < 0.001$), higher histologic grade ($p < 0.001$), increased mitotic count ($p = 0.002$), presence of tumor necrosis ($p < 0.001$), and expression of cIL13Ra1 ($p < 0.001$) (Table 2). The expression of cIL13Ra1 was significantly associated with higher histologic grade ($p = 0.030$) (Table 2).
| Histologic type                | No. | nIL4Rα positive | p    | cIL4Rα positive | p     | nIL13Rα1 positive | p     | cIL13Rα1 positive | p     |
|-------------------------------|-----|----------------|------|----------------|-------|------------------|-------|------------------|-------|
| Synovial sarcoma              | 15  | 10 (67%)       | 0.027| 12 (80%)       | <0.001| 8 (53%)          | 0.010 | 8 (53%)          | 0.077 |
| Leiomyosarcoma                | 13  | 8 (62%)        | 0.027| 8 (62%)        | <0.001| 10 (77%)        | 0.001 | 8 (62%)        |       |
| Undifferentiated sarcoma      | 10  | 8 (80%)        | 0.027| 9 (90%)        | <0.001| 7 (70%)        | 0.010 | 7 (70%)        |       |
| Liposarcoma, myxoid           | 9   | 0 (0%)         |      | 0 (0%)         |       | 0 (0%)          |       | 1 (11%)       |       |
| Liposarcoma, WD               | 4   | 1 (25%)        |      | 1 (25%)        |       | 1 (25%)        |       | 0 (0%)         |       |
| Liposarcoma, dedifferentiated | 3   | 0 (0%)         |      | 0 (0%)         |       | 1 (33%)        |       | 1 (33%)       |       |
| Rhabdomyosarcoma, alveolar    | 3   | 1 (33%)        |      | 3 (100%)       |       | 1 (33%)        |       | 1 (33%)       |       |
| Rhabdomyosarcoma, embryonal   | 2   | 1 (50%)        |      | 2 (100%)       |       | 0 (0%)         |       | 0 (0%)         |       |
| Rhabdomyosarcoma, pleomorphic | 1   | 0 (0%)         |      | 1 (100%)       |       | 0 (0%)         |       | 0 (0%)         |       |
| Rhabdomyosarcoma, spindle     | 1   | 1 (100%)       |      | 1 (100%)       |       | 1 (100%)       |       | 1 (100%)      |       |
| Myxofibrosarcoma              | 6   | 4 (67%)        |      | 3 (50%)        |       | 2 (33%)        |       | 2 (33%)       |       |
| MPNST                          | 5   | 2 (40%)        |      | 1 (20%)        |       | 3 (60%)        |       | 1 (20%)       |       |
| Epithelioid sarcoma           | 4   | 3 (75%)        |      | 3 (75%)        |       | 4 (100%)       |       | 4 (100%)      |       |
| Ewing sarcoma                 | 4   | 3 (75%)        |      | 3 (75%)        |       | 3 (75%)        |       | 2 (50%)       |       |
| Fibrosarcoma, adult           | 4   | 2 (50%)        |      | 4 (100%)       |       | 1 (25%)        |       | 2 (50%)       |       |
| Angiosarcoma                   | 3   | 3 (100%)       |      | 3 (100%)       |       | 3 (100%)       |       | 2 (67%)       |       |
| Low-grade myofibroblastic sarcoma | 2 | 2 (100%) |      | 2 (100%) |       | 0 (0%) |       | 0 (0%) |       |

Abbreviations: WD; well differentiated, MPNST; malignant peripheral nerve sheath tumor, nIL4Rα; nuclear expression of IL4Rα, cIL4Rα; cytoplasmic expression of IL4Rα, nIL13Rα1; nuclear expression of IL13Rα1, cIL13Rα1; cytoplasmic expression of IL13Rα1.
### Table 2
Clinicopathologic variables and the expression of IL4Rα and IL13Rα1 in soft-tissue sarcomas

| Characteristics | No. | nIL4Rα | cIL4Rα | nIL13Rα1 | cIL13Rα1 |
|----------------|-----|--------|--------|----------|----------|
|                |     | positive | p      | positive | p         | positive | p         |
| Age, y         |     |          |        |          |           |          |           |
| < 60           | 56  | 26 (46%) | 0.033  | 33 (59%) | 0.310     | 26 (46%) | 0.310     | 22 (39%) | 0.162     |
| ≥ 60           | 33  | 23 (70%) | 0.033  | 23 (70%) | 0.310     | 19 (58%) | 0.310     | 18 (55%) |           |
| Sex            |     |          |        |          |           |          |           |           |           |
| Female         | 37  | 19 (51%) | 0.553  | 22 (59%) | 0.568     | 15 (41%) | 0.111     | 13 (35%) | 0.117     |
| Male           | 52  | 30 (58%) | 0.310  | 34 (65%) | 0.310     | 30 (58%) | 0.310     | 27 (52%) |           |
| Stage          |     |          |        |          |           |          |           |           |           |
| I and II       | 36  | 12 (33%) | < 0.001 | 17 (47%) | 0.012     | 8 (22%)  | < 0.001   | 12 (33%) | 0.070     |
| III and IV     | 53  | 37 (70%) |          | 39 (74%) |           | 37 (70%) |           | 28 (53%) |           |
| Tumor size     |     |          |        |          |           |          |           |           |           |
| ≤ 5 cm         | 35  | 15 (43%) | 0.063  | 20 (57%) | 0.364     | 14 (40%) | 0.109     | 16 (46%) | 0.906     |
| > 5 cm         | 54  | 34 (63%) |          | 36 (67%) |           | 31 (57%) |           | 24 (44%) |           |
| LN metastasis  |     |          |        |          |           |          |           |           |           |
| Absence        | 77  | 39 (51%) | 0.034  | 45 (58%) | 0.027     | 35 (45%) | 0.015     | 34 (44%) | 0.705     |
| Presence       | 12  | 10 (83%) |          | 11 (92%) |           | 10 (83%) |           | 6 (50%)  |           |
| Distant metastasis | | 65  | 32 (49%) | 0.069  | 38 (58%) | 0.152     | 23 (35%) | < 0.001 | 26 (40%) | 0.123     |
| Absence        | 24  | 17 (71%) |          | 18 (75%) |           | 22 (92%) |           | 14 (58%) |           |
| Presence       | 41  | 28 (68%) |          | 31 (76%) |           | 29 (71%) |           | 23 (56%) |           |
| Histological grade | | 18  | 4 (22%) | 0.002  | 5 (28%)  | < 0.001 | 2 (11%)  | < 0.001 | 4 (22%) | 0.030     |
| Low            | 71  | 45 (63%) |          | 51 (72%) |           | 43 (61%) |           | 36 (51%) |           |
| High           | 45  | 4 (57%)  | 0.908  | 4 (57%)  | 0.742     | 2 (29%)  | 0.742     | 1 (14%)  | 0.225     |
| Tumor differentiation | | 82  | 45 (55%) |          | 52 (63%) |           | 52 (63%) |           | 43 (52%) |           |
| 2 and 3        | 36  | 12 (33%) | < 0.001 | 16 (44%) | 0.003     | 11 (31%) | 0.002     | 13 (36%) | 0.167     |
| Mitotic count  | 53  | 37 (70%) |          | 40 (75%) |           | 34 (64%) |           | 27 (51%) |           |
| 0–9/10 HPF     |     |          |        |          |           |          |           |           |           |
| > 9/10 HPF     | 48  | 21 (44%) | 0.002  | 25 (52%) | 0.022     | 16 (33%) | < 0.001 | 17 (35%) | 0.051     |
| Tumor necrosis |     |          |        |          |           |          |           |           |           |
| Absence        | 41  | 28 (68%) |          | 31 (76%) |           | 29 (71%) |           | 23 (56%) |           |
| Presence       | 49  | 20 (41%) | 0.003  | 23 (47%) | < 0.001   | 14 (29%) |           |           |           |

Abbreviations: nIL4Rα; nuclear expression of IL4Rα, cIL4Rα; cytoplasmic expression of IL4Rα, nIL13Rα1; nuclear expression of IL13Rα1, cIL13Rα1; cytoplasmic expression of IL13Rα1.
| Characteristics | No. | nIL4Rα | cIL4Rα | nIL13Rα1 | cIL13Rα1 |
|-----------------|-----|--------|--------|-----------|-----------|
| Positive        | 40  | 29 (73%) | 33 (83%) | 31 (78%) | < 0.001   |
| nIL13Rα1        | Negative | 44  | 13 (30%) | < 0.001 | 18 (41%) | < 0.001   |
| Positive        | 45  | 36 (80%) | 38 (84%) |           |           |
| cIL4Rα          | Negative | 33  | 3 (9%)  | < 0.001 |           |           |
| Positive        | 56  | 46 (82%) |         |           |           |

Abbreviations: nIL4Rα; nuclear expression of IL4Rα, cIL4Rα; cytoplasmic expression of IL4Rα, nIL13Rα1; nuclear expression of IL13Rα1, cIL13Rα1; cytoplasmic expression of IL13Rα1.

The expressions of IL4Rα and IL13Rα1 are associated with shorter survival of soft-tissue sarcoma patients

The factors significantly associated with OS or RFS in univariate analysis were age (OS; $p = 0.379$, RFS; $p = 0.047$), tumor stage (OS; $p < 0.001$, RFS; $p = 0.004$), lymph node metastasis (OS; $p = 0.006$, RFS; $p = 0.038$), distant metastasis (OS; $p < 0.001$, RFS; $p < 0.001$), histologic grade (OS; $p = 0.006$, RFS; $p = 0.006$), mitotic count (OS; $p = 0.002$, RFS; $p = 0.008$), tumor necrosis (OS; $p < 0.001$, RFS; $p = 0.004$), and the expression of nIL4Rα (OS; $p < 0.001$, RFS; $P < 0.001$), cIL4Rα (OS; $p < 0.001$, RFS; $p < 0.001$), nIL13Rα1 (OS; $p < 0.001$, RFS; $P < 0.001$), and cIL13Rα1 (OS; $p = 0.001$, RFS; $p = 0.002$) (Table 3). The nIL4Rα-positivity predicted a 5.249-fold [95% CI (95% confidential interval); 2.398–11.493] greater risk of death and a 3.750-fold (95% CI; 2.051–6.855) greater risk of relapse or death of STS patients (Table 3). The cIL4Rα-positivity predicted a 4.099-fold (95% CI; 1.799–9.339) greater risk of death and a 3.394-fold (95% CI; 1.782–6.464) greater risk of relapse or death of STS patients (Table 3). The nIL13Rα1-positivity predicted a 9.451-fold (95% CI; 3.938–22.683) greater risk of death and a 6.546-fold (95% CI; 3.499–12.248) greater risk of relapse or death of STS patients (Table 3). The cIL13Rα1-positivity predicted a 2.902-fold (95% CI; 1.510–5.579) greater risk of death and a 2.305-fold (95% CI; 1.353–3.924) greater risk of relapse or death of STS patients (Table 3). The Kaplan-Meier survival curves according to the expression of nIL4Rα, cIL4Rα, nIL13Rα1, and cIL13Rα1 are presented in Fig. 2.
Table 3
Univariate Cox proportional hazards regression analysis of overall survival and relapse-free survival in soft-tissue sarcoma patients

| Characteristics                        | No.   | OS   | RFS  |
|----------------------------------------|-------|------|------|
|                                        |       | HR (95% CI) | p    | HR (95% CI) | p    |
| Sex, male (vs. female)                 | 52/89 | 1.598 (0.834–3.064) | 0.158 | 1.239 (0.724–2.118) | 0.435 |
| Age, ≥ 60 (vs. < 60)                   | 23/89 | 1.330 (0.705–2.512) | 0.379 | 1.714 (1.007–2.917) | 0.047 |
| Stage, III and IV (vs. I and II)      | 53/89 | 4.540 (1.986–10.375) | < 0.001 | 2.342 (1.303–4.208) | 0.004 |
| Tumor size, > 5 cm (vs. ≤ 5 cm)       | 54/89 | 1.582 (0.802–3.120) | 0.186 | 1.157 (0.672–1.991) | 0.600 |
| LN metastasis, presence (vs. absence) | 12/89 | 2.834 (1.340–5.994) | 0.006 | 2.076 (1.043–4.134) | 0.038 |
| Distant metastasis, presence (vs. absence) | 24/89 | 5.976 (3.152–11.331) | < 0.001 | 4.097 (2.351–7.139) | < 0.001 |
| Histological grade, high (vs. low)    | 71/89 | 16.434 (2.237–120.748) | < 0.001 | 3.313 (1.411–7.777) | 0.006 |
| Tumor differentiation, 2 and 3 (vs. 1) | 82/89 | 2.041 (0.491–8.481) | 0.326 | 0.899 (0.357–2.260) | 0.820 |
| Mitotic count, ≥ 10/10 HPF (vs. 0–9/10 HPF) | 53/89 | 3.548 (1.620–7.772) | 0.002 | 2.196 (1.225–3.937) | 0.008 |
| Tumor necrosis, presence (vs. absence) | 41/89 | 4.792 (2.331–9.853) | < 0.001 | 2.209 (1.294–3.771) | 0.004 |
| nIL4Rα, positive (vs. negative)       | 49/89 | 5.249 (2.398–11.493) | < 0.001 | 3.750 (2.051–6.855) | < 0.001 |
| cIL4Rα, positive (vs. negative)       | 56/89 | 4.099 (1.799–9.339) | < 0.001 | 3.394 (1.782–6.464) | < 0.001 |
| nIL13Rα1, positive (vs. negative)     | 45/89 | 9.451 (3.938–22.683) | < 0.001 | 6.546 (3.499–12.248) | < 0.001 |
| cIL13Rα1, positive (vs. negative)     | 40/89 | 2.902 (1.510–5.579) | 0.001 | 2.305 (1.353–3.924) | 0.002 |

Abbreviations: OS, overall survival; RFS, relapse-free survival; HR, hazard ratio; 95% CI, 95% confidence interval, nIL4Rα; nuclear expression of IL4Rα, cIL4Rα; cytoplasmic expression of IL4Rα, nIL13Rα1; nuclear expression of IL13Rα1, cIL13Rα1; cytoplasmic expression of IL13Rα1.

Multivariate analysis was performed with the factors significantly associated with OS or RFS, which were age, tumor stage, lymph node metastasis, distant metastasis, histologic grade, tumor necrosis, and the expression of nIL4Rα, cIL4Rα, nIL13Rα1, and cIL13Rα1. Multivariate analysis revealed distant metastasis, nIL4Rα expression, and nIL13Rα1 expression as independent prognostic indicators of OS and RFS of STS patients (Table 4). The STS patients with nIL4Rα-positive tumors had a 3.920-fold (p = 0.002, 95% CI; 1.676–9.167) greater risk in OS analysis and a 2.196-fold (p = 0.022, 95% CI; 1.199–4.308) greater risk in RFS analysis compared with nIL4Rα-negative STS patients (Table 4). The STS patients with nIL13Rα1-positive tumor had a 3.397-fold (p = 0.016, 95% CI; 1.259–9.164) greater risk in OS analysis and a 3.554-fold (p < 0.001, 95% CI; 1.695–7.451) greater risk in RFS analysis compared with nIL13Rα1-negative STS patients (Table 4).
Table 4
Multivariate Cox regression analysis of overall survival and relapse-free survival in soft-tissue sarcoma patients

| Characteristics                        | OS              | RFS             |
|----------------------------------------|-----------------|-----------------|
|                                        | HR (95% CI)     | p       | HR (95% CI)     | p       |
| Distant metastasis, presence (vs. absence) | 3.665 (1.747–7.689) | < 0.001 | 2.160 (1.178–3.958) | 0.013  |
| nIL4Ra, positive (vs. negative)        | 3.920 (1.676–9.167) | 0.002  | 2.196 (1.119–4.308) | 0.022  |
| nIL13Ra1, positive (vs. negative)      | 3.397 (1.259–9.164) | 0.016  | 3.554 (1.695–7.451) | < 0.001 |

Abbreviations: OS, overall survival; RFS, relapse-free survival; HR, hazard ratio; 95% CI, 95% confidence interval, nIL4Ra; nuclear expression of IL4Ra; nIL13Ra1; nuclear expression of IL13Ra1.

Co-expression patterns of nuclear IL4Ra and nuclear IL13Ra1 are predictive for survival of soft-tissue sarcoma patients

In multivariate analysis, the expression of nIL4Ra and nIL13Ra1 were the independent indicators of OS and RFS of STS patients. In addition, based on the molecular relationship between IL4Ra and IL13Ra1 as components of the type II IL4R complex and their possible roles in cancer progression [2–4], we evaluated the prognostic significance of the co-expression pattern of nIL4Ra and nIL13Ra1 in STSs. At first, we sub-classified STSs according to the co-expression patterns of nIL4Ra and nIL13Ra1 into four subgroups: nIL4Ra−/nIL13Ra1−, nIL4Ra+/nIL13Ra1−, nIL4Ra−/nIL13Ra1+, and nIL4Ra+/nIL13Ra1+. The nIL4Ra+/nIL13Ra1− subgroup had the longest OS and RFS (10y-OS; 87%, 10y-RFS; 75%) and the nIL4Ra−/nIL13Ra1+ subgroup had the shortest OS and RFS (10y-OS; 13%, 10y-RFS; 0%) (Table 5) (Fig. 3a). This subgrouping of STSs was significantly associated with OS and RFS by both univariate and multivariate analysis (Multivariate analysis model 1: OS; overall p < 0.001, RFS; overall p < 0.001) (Table 6) (Fig. 3a). However, there was no significant difference in OS and RFS between the nIL4Ra+/nIL13Ra1− subgroup and nIL4Ra−/nIL13Ra1+ subgroup (Fig. 3a). Therefore, based on these results, we re-grouped STSs into three prognostic sub-groups: (nIL4Ra+/nIL13Ra1−), (nIL4Ra+/nIL13Ra1− and nIL4Ra−/nIL13Ra1+), and (nIL4Ra−/nIL13Ra1+). This subgrouping of STSs according to the co-expression patterns of nIL4Ra and nIL13Ra1 into three subgroups was significantly associated with OS and RFS by both univariate and multivariate analysis (Multivariate analysis model 2: OS; overall p < 0.001, RFS; overall p < 0.001) (Table 6) (Fig. 3b).

Table 5
Five- and ten-year overall survival and relapse-free survival according to co-expression patterns of nuclear IL4Ra and nuclear IL13Ra1

| Co-expression pattern of nIL4Ra and nIL13Ra1 | No. | 5y-OS (%) | 10y-OS (%) | 5y-RFS (%) | 10y-RFS (%) |
|---------------------------------------------|-----|-----------|------------|------------|-------------|
| Co-expression Model 1                       |     |           |            |            |             |
| nIL4Ra/nIL13Ra1, -/-                        | 31  | 87        | 87         | 75         | 75          |
| nIL4Ra/nIL13Ra1, +/-                        | 13  | 81        | 65         | 52         | 39          |
| nIL4Ra/nIL13Ra1, -/+                        | 9   | 67        | 36         | 22         | 11          |
| nIL4Ra/nIL13Ra1, +/-                        | 36  | 26        | 13         | 3          | 0           |
| Co-expression Model 2                       |     |           |            |            |             |
| nIL4Ra/nIL13Ra1, -/-                        | 31  | 87        | 87         | 75         | 75          |
| nIL4Ra/nIL13Ra1, +/- or -/+                 | 22  | 75        | 50         | 40         | 27          |
| nIL4Ra/nIL13Ra1, +/-                        | 36  | 26        | 13         | 3          | 0           |

Abbreviations: 5y-OS; overall survival rate at five years, 10y-OS; overall survival rate at ten years, 5y-RFS; relapse-free survival rate at five years, 10y-RFS; relapse-free survival rate at ten years, nIL4Ra; nuclear expression of IL4Ra; nIL13Ra1; nuclear expression of IL13Ra1.
Table 6
Univariate and multivariate Cox regression analysis of overall survival and relapse-free survival according to the co-expression patterns of nuclear IL4Rα and nuclear IL13Rα1 in soft-tissue sarcomas

| Characteristics | No. | OS | RFS |
|-----------------|-----|----|-----|
|                 |     | HR (95% CI) | p   | HR (95% CI) | p   |
| **Univariate analysis** |     |     |     |     |
| nIL4Rα/nIL13Rα1, -/- | 31/89 | 1 | < 0.001 | 1 | < 0.001 |
| +/-              | 13/89 | 3.230 (0.640-16.303) | 0.156 | 2.990 (1.048–8.535) | 0.041 |
| -/+              | 9/89  | 7.673 (1.916–30.738) | 0.004 | 7.670 (2.770-21.237) | < 0.001 |
| +/-              | 36/89 | 18.871 (5.553–64.130) | < 0.001 | 10.815 (4.648–25.169) | < 0.001 |
| nIL4Rα/nIL13Rα1, -/- | 31/89 | 1 | < 0.001 | 1 | < 0.001 |
| +/- or -/+       | 22/89 | 5.355 (1.434–20.004) | 0.013 | 4.424 (1.801–10.871) | 0.001 |
| +/+              | 36/89 | 19.504 (5.671–67.080) | < 0.001 | 10.791 (4.633–25.134) | < 0.001 |
| **Multivariate analysis Model 1** |     |     |     |     |
| Distant metastasis, presence (vs. absence) | 3.743 (1.762–7.952) | < 0.001 | 2.083 (1.127–3.849) | 0.019 |
| nIL4Rα/nIL13Rα1, -/- | 1 | < 0.001 | 1 | < 0.001 |
| +/-              | 3.140 (0.626–15.760) | 0.165 | 2.972 (1.041–8.486) | 0.042 |
| -/+              | 2.808 (0.610-12.924) | 0.185 | 4.827 (1.601–14.551) | 0.005 |
| +/-              | 11.927 (3.359–42.353) | < 0.001 | 8.729 (3.628–21.003) | < 0.001 |
| **Multivariate analysis Model 2** |     |     |     |     |
| Distant metastasis, presence (vs. absence) | 3.663 (1.836–7.307) | < 0.001 | 2.312 (1.305–4.095) | 0.004 |
| nIL4Rα/nIL13Rα1, -/- | 1 | < 0.001 | 1 | < 0.001 |
| +/- or -/+       | 2.947 (0.750-11.584) | 0.122 | 3.619 (1.447–9.052) | 0.006 |
| +/+              | 12.004 (3.396–42.433) | < 0.001 | 8.397 (3.491–20.197) | < 0.001 |

Abbreviations: OS, overall survival; RFS, relapse-free survival; HR, hazard ratio; 95% CI, 95% confidence interval, nIL4Rα; nuclear expression of IL4Rα, cIL4Rα; nIL13Rα1; nuclear expression of IL13Rα1.

Discussion

In this study, we have shown that the expression of IL4Rα and IL13Rα1 are associated with clinicopathological factors related to the progression of STSs, and there was a significant association between the expression of IL4Rα and IL13Rα1 in STSs. Furthermore, there was a positive correlation between the expression of mRNA IL4Rα and IL13Rα1 in glioblastoma multiform [9]. In addition, the expression of IL4Rα and IL13Rα1 were increased in meningioma compared with normal brain tissue [8] and were higher in invasive pituitary adenoma compared to non-invasive pituitary adenoma [7]. In STSs, the expression of mRNA of IL4Rα, cIL4Rα; nIL13Rα1; nuclear expression of IL4Rα and
IL13Ra1 (Pearson's $R = 0.15$, $p = 0.016$) in the GEPIA public database (http://gepia.cancer-pku.cn. accessed November 15, 2020) [23]. In addition, higher expression of IL4Ra and IL13Ra1 were associated with advanced clinicopathological factors of STSs such as higher tumor stage, cancer metastasis, higher histologic grade, increased mitosis, and tumor necrosis. Furthermore, nuclear and cytoplasmic expression of IL4Ra and IL13Ra1 were associated with shorter survival of STSs. Especially, individual and combined expression patterns of nuclear IL4Ra and IL13Ra1 were independent indicators of poor prognosis of STS patients. Consistently, although nuclear and cytoplasmic expression were not analyzed separately, higher expression of IL4Ra and IL13Ra1 were significantly associated with shorter cancer-specific survival and RFS of clear cell renal cell carcinoma patients [12]. Especially, clear cell renal cell carcinoma patients with co-positivity for the expression of IL4Ra and IL13Ra1 had the shortest survival time [12]. In addition, the prognostic significance of individual expression of IL4Ra or IL13Ra1 has been reported in various human cancers. Higher expression of mRNA and protein of IL4Ra was associated with shorter survival of mesothelioma patients [10]. In breast cancer, higher expression of IL13Ra1 was significantly associated with shorter OS and disease-specific survival [11]. Higher expression of IL13Ra1 mRNA was associated with poor prognosis of glioblastoma patients [9]. Therefore, targeting the IL4R complex might be a therapeutic strategy for cancers with poor prognosis that highly express IL4Ra and IL13Ra1.

The prognostic impact of the expression of IL4Ra and IL13Ra1 in human cancers is related to the role of IL4Ra/IL13Ra1 in cancer-related signaling. Although studies on the role of IL4Ra/IL13Ra1 in STSs have been limited, it has been reported that the IL4Ra/IL13Ra1 receptor complex is involved in tumorigenesis via mechanism the cell cycle, apoptosis, and cellular proliferation [1, 2, 12]. In renal cell carcinoma cells, knock-down of IL4Ra or IL13Ra1 induced cell cycle arrest and apoptosis by suppressing JAK2-mediated phosphorylation of FOXO3 [2]. In rhabdomyosarcoma cells, activation of IL4R with IL4 and IL13 ligands increased tumor growth through activation of STAT6, Akt, or MAPK pathways [16]. In 4T1 breast cancer cells, IL4Ra enhanced tumor growth by mediating IL4-related enhancement of glucose and glutamine metabolism [24]. The silencing of IL4Ra inhibited the growth and invasiveness of pancreatic cancer cells by suppressing the STAT3 and Akt pathways [25]. In colorectal cancer cells, IL13 induced epithelial-to-mesenchymal transition through the STAT6 pathway and was reversed with knock-down of IL13Ra1 [26]. However, there are controversial reports on the role of IL4R in tumorigenesis. In a transgenic mouse model with overexpression of IL4, IL4/IL4Ra suppressed the development of melanoma through activation of the P21-mediated STAT6 pathway and inhibition of anti-apoptotic BCL2 expression [27]. In addition, reduction of IL4R signaling was associated with increased initiation of colorectal cancer development, but reduced cancer progression [28]. This report emphasized that a therapeutic approach carefully targeting IL4R signaling according to the cancer progression stage could be effective [28]. Therefore, although most reports suggest the IL4R complex as a promising therapeutic target of human cancers, a tailored approach according to the specific subtype of cancer is likely to be the most effective.

In our results, both nuclear and cytoplasmic expression of IL4Ra and IL13Ra1 were significantly associated with the survival of STS patients. When considering the role of type II IL4R as a receptor for cytokines, IL4Ra and IL13Ra1 are expected to be localized in the cytoplasmic membrane. However, in this study, their expression in nuclei presented as a more powerful prognostic indicator of STSs compared with their cytoplasmic expression. Therefore, when we searched for the subcellular localization of IL4Ra and IL13Ra1 in a public database, nuclear expression of IL4Ra and IL13Ra1 was presented in The Human Protein Atlas database (https://www.proteinatlas.org. accessed November 15, 2020) [5, 29]. In addition, the expression of IL4Ra and/or IL13Ra1 was observed in both the cytoplasm and nuclei of human cancer tissue samples, such as clear cell renal cell carcinoma [12], squamous cell carcinoma [13], and lung cancer [30]. Moreover, when considering the nuclear and cytoplasmic expression of the molecules related to IL4Ra/IL13Ra1 such as JAK2 and STAT6 based on The Human Protein Atlas, the expression of IL4Ra/IL13Ra1 was expected in both cytoplasm and nuclei [5, 29]. Therefore, it is suggested that the nuclear localization of IL4Ra and IL13Ra1 might have a role in the progression of cancers. However, the significance of the nuclear localization of IL4Ra and IL13Ra1 in the progression of cancer is not clear. One possible explanation might be that IL4Ra/IL13Ra1 are involved in tumorigenesis in association with nuclear proteins related to tumor biology [12]. Recently, it has been reported that IL4Ra/IL13Ra1 interact with nuclear protein JAK2 and FOXO3 [30]. In renal cell carcinoma cells, the silencing of IL4Ra expression reduced interaction between JAK2 and FOXO3 and resulted in stabilizing FOXO3 [7]. Therefore, when considering the oncogenic role of JAK2 and tumor-suppressive role of FOXO3, nuclear localization of IL4Ra/IL13Ra1 exerts its role by involving JAK2-FOXO3 interaction in the progression of STSs.

In this study, higher expression of IL4Ra and IL13Ra1 were associated with progression and poor survival of STS patients. Therefore, IL4Ra/IL13Ra1 might be a potential therapeutic target for STS patients. Based on the characteristics of the IL4Ra/IL13Ra1 receptor complex that is activated by both IL4 and IL13 and it stimulates the JAK1/JAK2/STAT6 pathway in solid cancers, IL4/IL13, IL4Ra/IL13Ra1, and JAK1/JAK2/STAT6 might be good therapeutic targets for the treatment of malignant tumors expressing...
IL4Ra/IL13Ra1. In rhabdomyosarcoma cells, IL4 and IL13 activate cellular proliferation through the JAK/STAT signaling pathway, and blocking IL4R with a neutralizing antibody suppressed tumor progression [16]. Blocking of IL4Ra also induced the apoptosis of breast cancer cells [31, 32]. In renal cell carcinoma cells, knock-down of IL4Ra or IL13Ra1 and pharmacological inhibition of JAK2 induced cell cycle arrest and apoptosis of cancer cells [12]. Similarly, inhibition of JAK2, which is downstream of IL4R, delayed tumor growth in an osteosarcoma xenograft model [17]. In addition, as IL4R is highly expressed in human cancers, receptor-directed anti-tumor therapeutic approaches have been tested. AP-1 (human atherosclerotic plaque-specific peptide-1)-conjugated liposomal conjugate specifically targeted at IL4Ra, showed an anti-cancer effect on IL4Ra-overexpressing colon cancer cells [33]. Furthermore, with respect to treatment of human cancers, one of the important aspects for achieving successful treatment is overcoming the resistance of cancer cells to anti-cancer therapeutics; thus, the regulation of host anti-immune mechanisms is one of the promising therapeutic strategies, and IL4R also might be a potential target to overcome cancer resistance [3]. Colorectal cancer-related cancer-initiating cells evade immune surveillance through IL4/IL4R-mediated inhibition of T cell proliferation [34]. Blocking of IL4R with IL4Ra antagonist or anti-IL4 neutralizing antibodies sensitized CD133-expressing colon cancer stem cells to conventional the chemotherapeutics oxaliplatin and 5-FU [35]. Therefore, when considering the shorter survival of STS patients expressing IL4Ra and IL13Ra1, therapeutics targeting IL4Ra and IL13Ra1 might be novel therapeutic strategems for the treatment of STSs.

Conclusions

In conclusion, this study demonstrated that the expression of IL4Ra and IL13Ra1, especially when highly expressed in nuclei, were associated with advanced clinicopathological factors of STS such as higher tumor stage and high histologic grade, and predicted shorter survival of STS patients. Therefore, the expression of IL4Ra and IL13Ra1 might be used as novel prognostic indicators for STS patients. In addition, this study suggests that blocking of the IL4Ra/IL13Ra1 pathway might be a novel therapeutic stratagem for STSs.

Abbreviations

95% CI
95% confidence interval, cIL13Ra1: cytoplasmic expression of IL13Ra1, cIL4Ra: cytoplasmic expression of IL4Ra, HR: hazard ratio, IL13: interleukin-13, IL13R: interleukin-13 receptor, IL4: interleukin-4, IL4R: interleukin-4 receptor, nIL13Ra1: nuclear expression of IL13Ra1, nIL4Ra: nuclear expression of IL4Ra, OS: Overall survival, RFS: Relapse-free survival, STS: soft-tissue sarcoma

Declarations

Ethic approval and consent to participate

This study was approved by the institutional review board of Jeonbuk National University Hospital (IRB number, CUH 2015-09-024-002) and was performed in compliance with the Declaration of Helsinki. In this approval, written informed consent was waived because of the anonymous and retrospective nature of this study.

Consent for publication

Not applicable.

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the National Research Foundation of Korea (NRF) funded by the Korean government (MSIP) (grant numbers 2017R1A5A2015061 and 2017R1E1A1A01074533).
Author’s contributions

KMK, UKH, SHP, YJM, ZZ, AGA, ARA, HSP, JRK, and KYJ participated in the study design. KMK, UKH, SHP, YJM, ZZ, AGA, JRK, and KYJ performed the experiment. KMK, UKH, SHP, YJM, ARA, HSP, JRK, and KYJ were involved in data collection and data interpretation. KMK, JRK, and KYJ participated in the statistical analyses. KMK, UKH, SHP, YJM, ZZ, AGA, ARA, HSP, JRK, and KYJ wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments

We thank DB Leveson-Gower who provided medical writing services and Professor Keun Sang Kwon in the Department of Preventive Medicine for assisting with statistical analysis.

References

1. Hallett MA, Venmar KT, Fingleton B. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res. 2012;72:6338-43.
2. Bankaitis KV, Fingleton B. Targeting IL4/IL4R for the treatment of epithelial cancer metastasis. Clin Exp Metastasis. 2015;32:847-56.
3. Suzuki A, Leland P, Joshi BH, Puri RK. Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine. 2015;75:79-88.
4. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, Keegan AD, Garcia KC. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008;132:259-72.
5. Thul PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Alt Blal H, Alm T, Asplund A, Bjork L, Breckels LM, Backstrom A, Danielsson F, Fagerberg L, Fall J, Gatto L, Hjemmare M, Johansson F, Lee S, Lindskog C, Mulder J, Mulvey CM, Nilsson P, Oksvold P, Rockberg J, Schutten R, Schwenk JM, Sjostedt E, Skogs M, Stadler C, Sullivan DP, Tegel H, Winsnes C, Zhang C, Zwahlen M, Mardinoglu A, Ponten F, von Feilitzen K, Lilley KS, Uhlen M, Lundberg E. A subcellular map of the human proteome. Science. 2017;356.
6. Ito T, Suzuki S, Kanaji S, Shiraishi H, Ohta S, Arima K, Tanaka G, Tamada T, Honjo E, Garcia KC, Kuroki R, Izuhara K. Distinct structural requirements for interleukin-4 (IL-4) and IL-13 binding to the shared IL-13 receptor facilitate cellular tuning of cytokine responsiveness. J Biol Chem. 2009;284:24289-96.
7. Chen L, Liu Y, Hou Y, Kato Y, Sano H, Kanno T. Expression and structure of interleukin 4 receptor (IL-4R) complex in human invasive pituitary adenomas. Neurosci Lett. 2007;417:30-5.
8. Puri S, Joshi BH, Sarkar C, Mahapatra AK, Hussain E, Sinha S. Expression and structure of interleukin 4 receptors in primary meningeal tumors. Cancer. 2005;103:2132-42.
9. Han J, Puri RK. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor alpha1 and alpha2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme. J Neurooncol. 2018;136:463-74.
10. Burt BM, Bader A, Winter D, Rodig SJ, Bueno R, Sugarbaker DJ. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res. 2012;18:1568-77.
11. Park MH, Kwon HJ, Kim JR, Lee B, Lee SJ, Bae YK. Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer. Ann Surg Oncol. 2017;24:3780-7.
12. Kang MA, Lee J, Ha SH, Lee CM, Kim KM, Jang KY, Park SH. Interleukin4Ralpha (IL4Ralpha) and IL13Ralpha1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways. Cancers (Basel). 2019;11.
13. Kwon M, Kim JW, Roh JL, Park Y, Cho KJ, Choi SH, Nam SY, Kim SY, Lee BH. Recurrence and cancer-specific survival according to the expression of IL-4Ralpha and IL-13Ralpha1 in patients with oral cavity cancer. Eur J Cancer. 2015;51:177-85.
14. Ul-Haq Z, Naz S, Mesarik MA. Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box. Cytokine Growth Factor Rev. 2016;32:3-15.
15. Board WCoTE: Soft tissue and bone tumours, 5th edn. Lyon (France): International Agency for Research on Cancer; 2020.
16. Hosoyama T, Aslam MI, Abraham J, Prajapati SI, Nishijo K, Michalek JE, Zarzabal LA, Nelon LD, Guttridge DC, Rubin BP, Keller C. IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma. Clin Cancer Res. 2011;17:2757-66.

17. Yan J, Wang Q, Zou K, Wang L, Schwartz EB, Fuchs JR, Zheng Z, Wu J. Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma. Mol Med Rep. 2015;12:498-502.

18. Amin MB, American Joint Committee on Cancer., American Cancer Society.: AJCC cancer staging manual, 8th edn. Chicago IL: American Joint Committee on Cancer, Springer; 2017.

19. Allred D, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-68.

20. Ahn SW, Ahn AR, Ha SH, Hussein UK, Do Yang J, Kim KM, Park HS, Park SH, Yu HC, Jang KY. Expression of FAM83H and ZNF16 are associated with shorter survival of patients with gallbladder carcinoma. Diagn Pathol. 2020;15:63.

21. Kim KM, Hussein UK, Park SH, Kang MA, Moon YJ, Zhang Z, Song Y, Park HS, Bae JS, Park BH, Ha SH, Moon WS, Kim JR, Jang KY. FAM83H is involved in stabilization of beta-catenin and progression of osteosarcomas. J Exp Clin Cancer Res. 2019;38:267.

22. Hussein UK, Ha SH, Ahmed AG, Kim KM, Park SH, Kim CY, Kwon KS, Zhang Z, Lee SA, Park HS, Park BH, Lee H, Chung MJ, Moon WS, Kang MJ, Jang KY. FAM83H and SCRIB stabilize beta-catenin and stimulate progression of gastric carcinoma. Aging (Albany NY). 2020;12:11812-34.

23. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98-W102.

24. Venmar KT, Kimmel DW, Cliffel DE, Fingleton B. IL4 receptor alpha mediates enhanced glucose and glutamine metabolism to support breast cancer growth. Biochim Biophys Acta. 2015;1853:1219-28.

25. Traub B, Sun L, Ma Y, Xu P, Lemke J, Paschke S, Henne-Bruns D, Knippschild U, Kormann M. Endogenously Expressed IL-4Ralpha Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo. Int J Mol Sci. 2017;18.

26. Cao H, Zhang J, Liu H, Wan L, Zhang H, Huang Q, Xu E, Lai M. IL-13/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells. Oncotarget. 2016;7:61183-98.

27. Lee HL, Park MH, Song JK, Jung YY, Kim Y, Kim KB, Hwang DY, Yoon do Y, Song MJ, Han SB, Hong JT. Tumor growth suppressive effect of IL-4 through p21-mediated activation of STAT6 in IL-4Ralpha overexpressed melanoma models. Oncotarget. 2016;7:23425-38.

28. Ingram N, Northwood EL, Perry SL, Marston G, Snowden H, Taylor JC, Scott N, Bishop DT, Coletta PL, Hull MA. Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observations. Carcinogenesis. 2013;34:2341-9.

29. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C, Stenstrom A, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigiarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Lilienfeldtoft J, Persson L, Johansson F, Zawel M, von Heijne G, Nielsen J, Ponten F. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.

30. Todaro M, Lombardo Y, Francipane MG, Alea MP, Cammareri P, Iovino F, Di Stefano AB, Di Bernardo C, Agrausa A, Cordorelli G, Walczak H, Stassi G. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ. 2008;15:762-72.

31. Shaik AP, Shaik AS, Majwal AA, Faraj AA. Blocking Interleukin-4 Receptor alpha Using Polyethylene Glycol Functionalized Superparamagnetic Iron Oxide Nanocarriers to Inhibit Breast Cancer Cell Proliferation. Cancer Res Treat. 2017;49:322-9.

32. Venmar KT, Carter KJ, Hwang DG, Dozier EA, Fingleton B. IL4 receptor ILR4alpha regulates metastatic colonization by mammary tumors through multiple signaling pathways. Cancer Res. 2014;74:4329-40.

33. Yang CY, Liu HW, Tsai YC, Tseng JY, Liang SC, Chen CY, Lian WN, Wei MC, Lu M, Lu RH, Lin CH, Jiang JK. Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer. Cancer Biol Ther. 2015;16:1641-50.

34. Volonte A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, Bissolati M, Ghiardelli L, Orsenigo E, Ferrone S, Doglioni C, Stassi G, DellaBona P, Staudacher C, Parmiani G, Maccalli C. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol. 2014;192:523-32.

35. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1:389-402.